UCLA B-13: A phase 1b trial evaluating the safety of ribociclib, tucatinib, and trastuzumab in patients with metastatic, HER2+breast cancer and a multicenter, randomized, open-label, phase 2 study of preoperative treatment with ribociclib, trastuzumab, tucatinib, with or without fulvestrant versus docetaxel, carboplatin, trastuzumab, and pertuzumab in HR+/ HR-, HER2+breast cancer

被引：0
|
作者：
McAndrew, Nicholas Patrick [1 ]
Hurvitz, Sara A. [1 ]
Tetef, Merry L. [1 ]
Kivork, Christine [1 ]
Ikenouye, Larissa [1 ]
Slamon, Dennis J. [1 ]
机构：
[1] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS1116
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Ribociclib Plus Trastuzumab in Advanced HER2-Positive Breast Cancer: Results of a Phase 1b/2 Trial
    Goel, Shom
    Pernas, Sonia
    Tan-Wasielewski, Zhenying
    Barry, William T.
    Bardia, Aditya
    Rees, Rebecca
    Andrews, Chelsea
    Tahara, Rie Kawabori
    Trippa, Lorenzo
    Mayer, Erica L.
    Winer, Eric P.
    Spring, Laura M.
    Tolaney, Sara M.
    CLINICAL BREAST CANCER, 2019, 19 (06) : 399 - 404
  • [2] Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer
    Spring, Laura M.
    Clark, Shealagh L.
    Li, Tianyu
    Goel, Shom
    Tayob, Nabihah
    Viscosi, Elene
    Abraham, Elizabeth
    Juric, Dejan
    Isakoff, Steven J.
    Mayer, Erica
    Moy, Beverly
    Supko, Jeffrey G.
    Tolaney, Sara M.
    Bardia, Aditya
    NPJ BREAST CANCER, 2021, 7 (01)
  • [3] Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer
    Laura M. Spring
    Shealagh L. Clark
    Tianyu Li
    Shom Goel
    Nabihah Tayob
    Elene Viscosi
    Elizabeth Abraham
    Dejan Juric
    Steven J. Isakoff
    Erica Mayer
    Beverly Moy
    Jeffrey G. Supko
    Sara M. Tolaney
    Aditya Bardia
    npj Breast Cancer, 7
  • [4] Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study
    Murthy, Rashmi
    Borges, Virginia F.
    Conlin, Alison
    Chaves, Jorge
    Chamberlain, Marc
    Gray, Todd
    Vo, Alex
    Hamilton, Erika
    LANCET ONCOLOGY, 2018, 19 (07): : 880 - 888
  • [5] Efficacy, safety, and predictive biomarkers of dalpiciclib combined with letrozole, pertuzumab and trastuzumab as neoadjuvant therapy in HR+/HER2+breast cancer: A phase II study.
    Liang, Xinrui
    Wu, Jing
    Zhang, Ningning
    Zeng, Xiaohua
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [6] Trial in progress: A phase 1b/2 study of the PARP inhibitor niraparib in combination with trastuzumab in patients with metastatic HER2+breast cancer (TBCRC 050).
    Stringer-Reasor, Erica Michelle
    Li, Yufeng
    Witherspoon, Felicia
    Specht, Jennifer M.
    Mesias, Jesus Del Santo Anampa
    Nanda, Rita
    Dees, Elizabeth Claire
    Wolff, Antonio C.
    Krop, Ian E.
    Lin, Nancy U.
    Rimawi, Mothaffar F.
    Yang, Eddy Shih-Hsin
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [7] Tucatinib-trastuzumab-capecitabine for treatment of leptomeningeal metastasis in HER2+breast cancer: TBCRC049 phase 2 study results.
    O'Brien, Barbara Jane
    Murthy, Rashmi Krishna
    Berry, Donald A.
    Raghavendra, Akshara Singareeka
    Gule-Monroe, Maria
    Johnson, Jason M.
    Schwartz-Gomez, Jill
    Topletz-Erickson, Ariel
    Lobbous, Mina
    Melisko, Michelle E.
    Morikawa, Aki
    Ferguson, Sherise D.
    De Groot, John Frederick
    Krop, Ian E.
    Valero, Vicente
    Rimawi, Mothaffar F.
    Wolff, Antonio C.
    Tripathy, Debashish
    Lin, Nancy U.
    Stringer-Reasor, Erica Michelle
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [8] A phase 1b/2 study of ribociclib plus trastuzumab for the treatment of advanced, treatment-refractory HER2-positive breast cancer
    Goel, S.
    Spring, L.
    Rees, R.
    Andrews, C.
    Tahara, R. K.
    Mayer, E. L.
    Bardia, A.
    Winer, E. P.
    Tolaney, S. M.
    CANCER RESEARCH, 2019, 79 (04)
  • [9] Phase I, open-label study evaluating the safety and tolerability of LJM716, BYL719 and trastuzumab in patients with metastatic HER2+breast cancer
    Shah, Payal D.
    Chandarlapaty, Sarat
    Ulaner, Gary
    Zamora, Stephen
    Sterlin, Valentina
    Iasonos, Alexia
    Dickler, Maura N.
    Moynahan, Mary Ellen
    Hudis, Clifford A.
    Baselga, Jose
    Modi, Shanu
    CANCER RESEARCH, 2015, 75
  • [10] Final overall survival (OS) for abemaciclib plus trastuzumab plus /- fulvestrant versus trastuzumab plus chemotherapy in patients with HR+, HER2+advanced breast cancer (monarcHER): A randomized, open-label, phase II trial
    Andre, F.
    Nadal, J. C.
    Denys, H.
    Goel, S.
    Litchfield, L. M.
    Appiah, A.
    Chen, Y.
    Tolaney, S. M.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1386 - S1387
12345